{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:37:19Z","timestamp":1794490639229,"version":"4.9.1"},"reference-count":81,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1097\/01.ftd.0000168293.48226.57","type":"journal-article","created":{"date-parts":[[2005,9,20]],"date-time":"2005-09-20T04:01:51Z","timestamp":1127188911000},"page":"655-665","source":"Crossref","is-referenced-by-count":280,"title":["Pharmacokinetics and Pharmacodynamics in Clinical Use of Scopolamine"],"prefix":"10.1097","volume":"27","author":[{"given":"Ulf D","family":"Renner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Oertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilhelm","family":"Kirch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-19-20210129","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1399-6576.1993.tb03780.x","article-title":"Pharmacokinetics and related pharmacodynamics of anticholinergic drugs.","volume":"37","author":"Ali-Melkkila","year":"1993","journal-title":"Acta Anaesthesiol Scand"},{"key":"R2-19-20210129","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2165\/00003088-198815020-00003","article-title":"Pharmacokinetic considerations in the use of newer transdermal formulations.","volume":"15","author":"Ridout","year":"1988","journal-title":"Clin Pharmacokinet"},{"key":"R3-19-20210129","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1021\/js950327b","article-title":"Bioavailability of intranasal scopolamine in normal subjects.","volume":"85","author":"Putcha","year":"1996","journal-title":"J Pharm Sci"},{"key":"R4-19-20210129","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0928-0987(01)00107-5","article-title":"Scopolamine nasal spray in motion sickness: a randomised, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo.","volume":"13","author":"Klocker","year":"2001","journal-title":"Eur J Pharm Sci"},{"key":"R5-19-20210129","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/jop.1990.6.61","article-title":"Systemic absorption of ocular scopolamine in patients.","volume":"6","author":"Lahdes","year":"1990","journal-title":"J Ocul Pharmacol"},{"key":"R6-19-20210129","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1399-6576.1998.tb04924.x","article-title":"Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites.","volume":"42","author":"Kentala","year":"1998","journal-title":"Acta Anaesthesiol Scand"},{"key":"R7-19-20210129","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1399-6576.1988.tb02691.x","article-title":"Pharmacokinetic implications for the clinical use of atropine, scopolamine and glycopyrrolate.","volume":"32","author":"Kanto","year":"1988","journal-title":"Acta Anaesthesiol Scand"},{"key":"R8-19-20210129","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/BF00543495","article-title":"Comparison of radioreceptor assay and radioimmunoassay for atropine: pharmacokinetic application.","volume":"26","author":"Aaltonen","year":"1984","journal-title":"Eur J Clin Pharmacol"},{"key":"R9-19-20210129","first-page":"121","article-title":"Scopolamine bioavailability in combined oral and transdermal delivery.","volume":"296","author":"Nachum","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"R10-19-20210129","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0378-4347(00)00433-3","article-title":"Determination of scopolamine in human serum and microdialysis samples by liquid chromatography-tandem mass spectrometry.","volume":"750","author":"Oertel","year":"2001","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"R11-19-20210129","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/bmc.1130060410","article-title":"Liquid chromatographic determination of hyoscine (scopolamine) in urine using solid phase extraction.","volume":"6","author":"Whelpton","year":"1992","journal-title":"Biomed Chromatogr"},{"key":"R12-19-20210129","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/0378-4347(91)80622-J","article-title":"Analysis of tropane alkaloids with thermospray high-performance liquid chromatography-mass spectrometry.","volume":"562","author":"Auriola","year":"1991","journal-title":"J Chromatogr"},{"key":"R13-19-20210129","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/(SICI)1522-2683(19991101)20:17<3402::AID-ELPS3402>3.0.CO;2-E","article-title":"Capillary electrophoresis-diode array detection-electrospray mass spectrometry for the analysis of selected tropane alkaloids in plant extracts.","volume":"20","author":"Mateus","year":"1999","journal-title":"Electrophoresis"},{"key":"R14-19-20210129","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1023\/A:1007551927177","article-title":"Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects.","volume":"17","author":"Ahmed","year":"2000","journal-title":"Pharm Res"},{"key":"R15-19-20210129","doi-asserted-by":"crossref","first-page":"523","DOI":"10.5414\/CPP38523","article-title":"Influence of grapefruit juice on scopolamine pharmacokinetics and pharmacodynamics in healthy male and female subjects.","volume":"38","author":"Ebert","year":"2000","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R16-19-20210129","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/jps.2600640220","article-title":"Submicrogram assay for scopolamine in plasma and urine.","volume":"64","author":"Bayne","year":"1975","journal-title":"J Pharm Sci"},{"key":"R17-19-20210129","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/j.1552-4604.1998.tb04812.x","article-title":"Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration.","volume":"38","author":"Ebert","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"R18-19-20210129","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0378-4347(00)82391-9","article-title":"Electron-impact ionization detection of scopolamine by gas chromatography-mass spectrometry in rat plasma and brain.","volume":"528","author":"Deutsch","year":"1990","journal-title":"J Chromatogr"},{"key":"R19-19-20210129","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0378-4347(96)00095-3","article-title":"Determination of scopolamine in human serum by gas chromatography-ion trap tandem mass spectrometry.","volume":"682","author":"Oertel","year":"1996","journal-title":"J Chromatogr B Biomed Appl"},{"key":"R20-19-20210129","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/00912700122009836","article-title":"Pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effects of scopolamine in healthy volunteers.","volume":"41","author":"Ebert","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"R22-19-20210129","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/00003088-199426020-00005","article-title":"Pharmacokinetic characterisation of transdermal delivery systems.","volume":"26","author":"Berner","year":"1994","journal-title":"Clin Pharmacokinet"},{"key":"R24-19-20210129","first-page":"325","article-title":"Use of percutaneous absorption for systemic administration of drugs.","volume":"215","author":"Shaw","year":"1975","journal-title":"The Pharmaceutical Journal"},{"key":"R25-19-20210129","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0731-7085(83)80048-X","article-title":"A comparison of plasma levels of hyoscine after oral and transdermal administration.","volume":"1","author":"Muir","year":"1983","journal-title":"J Pharm Biomed Anal"},{"key":"R27-19-20210129","first-page":"106","article-title":"Development and application of a radioreceptor assay for scopolamine.","volume":"38","author":"Ensing","year":"1988","journal-title":"Arzneimittelforschung"},{"key":"R28-19-20210129","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0928-0987(97)00058-4","article-title":"A semi-automated solid-phase extraction and radioreceptor assay for the analysis of scopolamine in urine and plasma.","volume":"5","author":"Bosman","year":"1997","journal-title":"Eur J Pharm Sci"},{"key":"R29-19-20210129","first-page":"282","article-title":"Comparison of transdermal and intravenous administration of scopolamine.","volume":"29","author":"Schmitt","year":"1981","journal-title":"[abstract] Clin Pharmacol Ther"},{"key":"R30-19-20210129","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/jps.2600671010","article-title":"Pharmacokinetics of drug permeation through human skin.","volume":"67","author":"Chandrasekaran","year":"1978","journal-title":"J Pharm Sci"},{"key":"R31-19-20210129","first-page":"1096","article-title":"Prevention of experimental motion sickness by scopolamine absorbed through the skin.","volume":"47","author":"Graybiel","year":"1976","journal-title":"Aviat Space Environ Med"},{"key":"R32-19-20210129","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3109\/00016488509182265","article-title":"Transdermally administered scopolamine vs. dimenhydrinate. I. Effect on nausea and vertigo in experimentally induced motion sickness.","volume":"99","author":"Pyykko","year":"1985","journal-title":"Acta Otolaryngol"},{"key":"R33-19-20210129","first-page":"994","article-title":"Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy.","volume":"54","author":"Homick","year":"1983","journal-title":"Aviat Space Environ Med"},{"key":"R34-19-20210129","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/BF00544360","article-title":"Effects of transdermal scopolamine upon psychological test performance at sea.","volume":"28","author":"Parrott","year":"1985","journal-title":"Eur J Clin Pharmacol"},{"key":"R35-19-20210129","first-page":"337","article-title":"Experimental motion sickness: efficacy of transdermal scopolamine plus ephedrine.","volume":"52","author":"Graybiel","year":"1981","journal-title":"Aviat Space Environ Med"},{"key":"R36-19-20210129","first-page":"467","article-title":"Rate of absorption of scopolamine after application of Scopoderm-TTS.","volume":"66","author":"Doweck","year":"1995","journal-title":"[abstract] Aviat Space Environ Med"},{"key":"R38-19-20210129","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/jps.2600760413","article-title":"A sensitive radioreceptor assay for determining scopolamine concentrations in plasma and urine.","volume":"6","author":"Cintron","year":"1987","journal-title":"J Pharm Sci"},{"key":"R39-19-20210129","first-page":"1","article-title":"Transdermal scopolamine: a review of its effects upon motion sickness, psychological performance, and physiological functioning.","volume":"60","author":"Parrott","year":"1989","journal-title":"Aviat Space Environ Med"},{"key":"R40-19-20210129","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/00003495-198529030-00001","article-title":"Transdermal hyoscine (scopolamine). A preliminary review of its pharmacodynamic properties and therapeutic efficacy.","volume":"29","author":"Clissold","year":"1985","journal-title":"Drugs"},{"key":"R41-19-20210129","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/bdd.2510140804","article-title":"Pharmacokinetics of anticholinergic drugs and brain muscarinic receptor alterations in streptozotocin diabetic rats.","volume":"14","author":"Nakashima","year":"1993","journal-title":"Biopharm Drug Dispos"},{"key":"R42-19-20210129","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1015916423156","article-title":"Pharmacokinetics and oral bioavailability of scopolamine in normal subjects.","volume":"6","author":"Putcha","year":"1989","journal-title":"Pharm Res"},{"key":"R43-19-20210129","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1399-6576.1989.tb02950.x","article-title":"Pharmacokinetics of scopolamine during caesarean section relationship between serum concentration and effect.","volume":"33","author":"Kanto","year":"1989","journal-title":"Acta Anaesthesiol Scand"},{"key":"R44-19-20210129","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1515\/bchm2.1968.349.1.741","article-title":"[Studies on the metabolism of tropane alkaloids. 8.","volume":"349","author":"Werner","year":"1968","journal-title":"Chemical analysis of ()-scopolamine metabolism in several mammals] Hoppe Seylers Z Physiol Chem"},{"key":"R45-19-20210129","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3109\/00498259109043204","article-title":"Metabolism in vivo of the tropane alkaloid, scopolamine, in several mammalian species.","volume":"21","author":"Wada","year":"1991","journal-title":"Xenobiotica"},{"key":"R46-19-20210129","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3109\/00498259409043284","article-title":"Sulphotransferase-dependent dehydration of atropine and scopolamine in guinea pig.","volume":"24","author":"Wada","year":"1994","journal-title":"Xenobiotica"},{"key":"R47-19-20210129","first-page":"487","article-title":"beta-Glucuronide and sulphate conjugation of scopolamine and glycopyrrolate.","volume":"28","author":"Kentala","year":"1990","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"R48-19-20210129","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/jat.2550020607","article-title":"Toxic alkaloids and their interaction with microsomal cytochrome P-450 in vitro.","volume":"2","author":"Peeples","year":"1982","journal-title":"J Appl Toxicol"},{"key":"R49-19-20210129","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0162-0134(89)80034-0","article-title":"Demethylation of tertiary amines by a reconstituted cytochrome P-450 enzyme system: kinetics of oxygen consumption and hydrogenperoxide formation.","volume":"37","author":"Ristau","year":"1989","journal-title":"J Inorg Biochem"},{"key":"R50-19-20210129","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00003088-199426020-00002","article-title":"Grapefruit juice and drugs. How significant is the interaction?","volume":"26","author":"Bailey","year":"1994","journal-title":"Clin Pharmacokinet"},{"key":"R51-19-20210129","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0009-9236(95)90048-9","article-title":"The fate of naringin in humans: A key to grapefruit juice-drug interactions?","volume":"58","author":"Fuhr","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"R52-19-20210129","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1046\/j.1365-2125.1996.42615.x","article-title":"Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue.","volume":"42","author":"Kivisto","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"R53-19-20210129","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00002018-199818040-00002","article-title":"Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance.","volume":"18","author":"Fuhr","year":"1998","journal-title":"Drug Saf"},{"key":"R54-19-20210129","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0006-2952(92)90010-G","article-title":"Effect of age and gender on the activity of human hepatic CYP3A.","volume":"44","author":"Hunt","year":"1992","journal-title":"Biochem Pharmacol"},{"key":"R57-19-20210129","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0006-2952(66)90165-1","article-title":"Effects of norethynodrel and progesterone on hepatic drug-metabolizing enzyme systems.","volume":"15","author":"Juchau","year":"1966","journal-title":"Biochem Pharmacol"},{"key":"R58-19-20210129","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0002-9378(70)90301-7","article-title":"The influence of pregnancy and oral contraceptive steroids on the concentration of plasma proteins.","volume":"108","author":"Song","year":"1970","journal-title":"Am J Obstet Gynecol"},{"key":"R59-19-20210129","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/00003088-198409030-00001","article-title":"Sex-related differences in drug disposition in man.","volume":"9","author":"Wilson","year":"1984","journal-title":"Clin Pharmacokinet"},{"key":"R60-19-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00426592","article-title":"Studies on human memory: the interaction of diazepam, scopolamine, and physostigmine.","volume":"52","author":"Ghoneim","year":"1977","journal-title":"Psychopharmacology (Berl)"},{"key":"R61-19-20210129","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000118365","article-title":"Effects of scopolamine (0.25-0.75 mg i.m.) on the quantitative EEG and the neuropsychological status of healthy volunteers.","volume":"17","author":"Sannita","year":"1987","journal-title":"Neuropsychobiology"},{"key":"R62-19-20210129","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/hup.470030106","article-title":"An investigation of the range of cognitive impairments induced by scopolamine-0.6 mg s.c.","volume":"3","author":"Wesnes","year":"1988","journal-title":"Hum Psychopharmacol"},{"key":"R63-19-20210129","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0165-0173(95)00016-X","article-title":"Acetylcholine: a neurotransmitter for learning and memory?","volume":"21","author":"Blokland","year":"1996","journal-title":"Brain Res Rev"},{"key":"R64-19-20210129","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1469-185X.1992.tb01191.x","article-title":"The functional role of the mesotelencephalic dopamine systems.","volume":"67","author":"Dunnett","year":"1992","journal-title":"Biol Rev"},{"key":"R65-19-20210129","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","article-title":"The cholinergic hypothesis of geriatric memory dysfunction.","volume":"217","author":"Bartus","year":"1982","journal-title":"Science"},{"key":"R66-19-20210129","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ana.410100203","article-title":"Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis.","volume":"10","author":"Whitehouse","year":"1981","journal-title":"Ann Neurol"},{"key":"R67-19-20210129","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0165-0173(80)90011-9","article-title":"Cholinergic projections from magnocellular nuclei of the basal forebrain to cortical areas in rats.","volume":"2","author":"Wenk","year":"1980","journal-title":"Brain Res"},{"key":"R68-19-20210129","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1001\/archpsyc.1987.01800170032006","article-title":"Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls: a dose-response study.","volume":"44","author":"Sunderland","year":"1987","journal-title":"Arch Gen Psychiat"},{"key":"R69-19-20210129","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1046\/j.1365-2362.1998.00393.x","article-title":"Scopolamine model of dementia: electroencephalogram findings and cognitive performance.","volume":"28","author":"Ebert","year":"1998","journal-title":"Eur J Clin Invest"},{"key":"R72-19-20210129","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1126\/science.3037705","article-title":"Identification of a family of muscarinic acetylcholine receptor genes.","volume":"237","author":"Bonner","year":"1987","journal-title":"Science"},{"key":"R74-19-20210129","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1006\/cbir.1996.0023","article-title":"Muscarinic acetylcholine receptor subtype mRNAs in human and rat vestibular periphery.","volume":"20","author":"Wackym","year":"1996","journal-title":"Cell Biol Int"},{"key":"R75-19-20210129","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3233\/VES-2000-10203","article-title":"The effects of scopolamine and cyclizine on visual-vestibular interaction in humans.","volume":"10","author":"Gowans","year":"2000","journal-title":"J Vestib Res"},{"key":"R76-19-20210129","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0196-0709(84)80013-7","article-title":"Efferent innervation of the labyrinth.","volume":"5","author":"Gacek","year":"1984","journal-title":"Am J Otolaryngol"},{"key":"R77-19-20210129","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000138503","article-title":"Muscarinic receptor subtypes and the selectivity of agonists and antagonists.","volume":"37","author":"Birdsall","year":"1988","journal-title":"Pharmacology"},{"key":"R78-19-20210129","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/BF00168807","article-title":"Complex dose-response curves of atropine in man explained by different functions M1- and M2-cholinoceptors.","volume":"338","author":"Wellstein","year":"1988","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"R79-19-20210129","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/j.1365-2044.1983.tb12525.x","article-title":"Gycopyrrolate: pharmacology and clinical use.","volume":"38","author":"Mirakhur","year":"1983","journal-title":"Anaesthesia"},{"key":"R80-19-20210129","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1399-6576.1989.tb02956.x","article-title":"Glycopyrrolate: pharmacokinetics and some pharmacodynamic findings.","volume":"33","author":"Ali-Melkkila","year":"1989","journal-title":"Acta Anaesthesiol Scand"},{"key":"R81-19-20210129","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/cpt1969103395","article-title":"Scopolamine on heart rate in man.","volume":"10","author":"Gravenstein","year":"1968","journal-title":"Clin Pharmacol Ther"},{"key":"R82-19-20210129","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/bja\/50.6.591","article-title":"Comparative study of the effects of oral and i.m. atropine and hyoscine in volunteers.","volume":"50","author":"Mirakhur","year":"1978","journal-title":"Br J Anaesth"},{"key":"R83-19-20210129","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2125.1980.tb01724.x","article-title":"Test of autonomic function in assessing centrally-acting drugs.","volume":"10","author":"Turner","year":"1980","journal-title":"Br J Clin Pharmacol"},{"key":"R84-19-20210129","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3181\/00379727-86-21150","article-title":"Contribution to the pharmacology of apoatropine and its methyl bromide.","volume":"86","author":"Krantz","year":"1954","journal-title":"Proc Soc Exp Biol Med"},{"key":"R85-19-20210129","first-page":"323","article-title":"The effects of scopolamine and ancillary analgesics upon the fetal heart rate recording.","volume":"25","author":"Ayromlooi","year":"1980","journal-title":"J Reprod Med"},{"key":"R86-19-20210129","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1542\/peds.66.2.329","article-title":"Scopolamine toxicity in a newborn.","volume":"66","author":"Evens","year":"1980","journal-title":"[letter] Pediatrics"},{"key":"R88-19-20210129","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/0002-9610(76)90019-2","article-title":"Freys syndrome.","volume":"131","author":"Bednarek","year":"1976","journal-title":"Am J Surg"},{"key":"R89-19-20210129","first-page":"155","article-title":"Studies of the toxicity of drugs in subcutaneous, intragastric and intraduodenal administration in rats.","volume":"180","author":"Stockhaus","year":"1969","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"R90-19-20210129","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0027-5107(83)90056-8","article-title":"Bacterial mutagenicity investigation of epoxides: drugs, drug metabolites, steroids and pesticides.","volume":"111","author":"Glatt","year":"1983","journal-title":"Mutat Res"},{"key":"R91-19-20210129","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1600-0773.1986.tb00166.x","article-title":"Pharmacokinetics and clinical effects of scopolamine in caesarean section patients.","volume":"59","author":"Pihlajamaki","year":"1986","journal-title":"Acta Pharmacol Toxicol (Copenh)"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00003453-199437021-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:59:53Z","timestamp":1785855593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007691-200510000-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":81,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.ftd.0000168293.48226.57","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}